Phase 1 Open Label Trial of MST-0312 Alone and in Combination in Subjects With Solid Malignancies

Inclusion Criteria

• •Male and female subjects of any ethnic origin, aged 18 years and over.
• •Must have given written informed consent and must be able to understand the full nature and purpose of the trial, including possible risks and adverse effects.
• •Subject must have a solid malignancy (non-small cell lung cancer (NSCLC), melanoma, bladder cancer, colorectal cancer (CRC) and triple negative breast cancer (TNBC)).
• •An ECOG performance status of 0 or 1 with no deterioration over the previous two weeks.
• •Willing to permit access to stored historical tumour tissue and prior tumour radiological assessments, cancer treatment history, including response to treatment, and tumour biomarker data, where available.
• •Willing and able to comply with all scheduled visits, treatment plans, laboratory tests, and other trial procedures.